You are here
Tocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8
SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2019 financial results and business progress on Thursday, August 8, 2019, after the close of the U.S. financial markets.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient's immune system against their own cancer. Tocagen's lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a pivotal Phase 3 trial (Toca 5) for recurrent high grade glioma (HGG), a disease with significant unmet medical need. The U.S. Food and Drug Administration awarded Tocagen an orphan drug grant for the Toca 5 trial and has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of recurrent HGG. The European Medicines Agency has granted Toca 511 PRIME (PRIority MEdicines) designation for the treatment of high grade glioma. For more information about Tocagen, visit www.tocagen.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/tocagen-to-report-second-quarter-2019-financial-results-and-business-updates-on-thursday-august-8-300894903.html
SOURCE Tocagen Inc.